127 related articles for article (PubMed ID: 3839284)
1. Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.
Letendre L; Hinemann V; Hoagland HC; Kovach JS
Med Pediatr Oncol; 1985; 13(4):232-4. PubMed ID: 3839284
[TBL] [Abstract][Full Text] [Related]
2. [AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Büchner T
Onkologie; 1985 Jun; 8(3):181-4. PubMed ID: 3895100
[TBL] [Abstract][Full Text] [Related]
3. [Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Kirchhof B; Stenzinger W; Büchner T
Onkologie; 1984 Aug; 7(4):214-6. PubMed ID: 6384864
[TBL] [Abstract][Full Text] [Related]
4. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
[TBL] [Abstract][Full Text] [Related]
5. High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Cassileth PA; Lyman GH; Bennett JM; Glick JH; Oken MM
Am J Clin Oncol; 1984 Aug; 7(4):361-3. PubMed ID: 6547566
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
Abrams RA; Hanson G; Hansen RM; Anderson T
Cancer Treat Rep; 1986 Apr; 70(4):535. PubMed ID: 3754490
[No Abstract] [Full Text] [Related]
7. Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Arlin ZA
Cancer Treat Rep; 1983 Nov; 67(11):967-70. PubMed ID: 6357436
[No Abstract] [Full Text] [Related]
8. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Arlin ZA; Gaddipati J; Ahmed T; Mittelman A; Friedland M; Rieber E
Cancer Treat Rep; 1985 Sep; 69(9):1001-2. PubMed ID: 3839713
[TBL] [Abstract][Full Text] [Related]
10. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
Carella AM; Santini G; Martinengo M; Nati S; Giordano D; Congiu A; Cerri R; Damasio E; Risso M; Rossi E
Haematologica; 1985; 70(1):39-43. PubMed ID: 2408974
[No Abstract] [Full Text] [Related]
11. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
[TBL] [Abstract][Full Text] [Related]
12. [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Ogawa M
Gan To Kagaku Ryoho; 1986 May; 13(5):1829-36. PubMed ID: 3754711
[TBL] [Abstract][Full Text] [Related]
13. Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Maschmeyer G; Hiddemann W; Kreutzmann H; Wendt F
Onkologie; 1987 Feb; 10(1):18-21. PubMed ID: 3295621
[TBL] [Abstract][Full Text] [Related]
14. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
Hiddemann W; Urbanitz D; Preusser P; Achterrath W; Büchner T
Hematol Oncol; 1989; 7(4):267-73. PubMed ID: 2737607
[TBL] [Abstract][Full Text] [Related]
16. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
Steuber CP; Holbrook T; Camitta B; Land VJ; Sexauer C; Krischer J
Invest New Drugs; 1991 May; 9(2):181-4. PubMed ID: 1714886
[TBL] [Abstract][Full Text] [Related]
17. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
[TBL] [Abstract][Full Text] [Related]
18. Amsacrine in refractory acute leukemia.
Griffin JD; Maguire ME; Mayer RJ
Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Hines JD; Oken MM; Mazza JJ; Keller AM; Streeter RR; Glick JH
J Clin Oncol; 1984 Jun; 2(6):545-9. PubMed ID: 6233399
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Miller LP; Miller DR; Tan CT
Cancer Treat Rep; 1983 May; 67(5):439-43. PubMed ID: 6189604
[No Abstract] [Full Text] [Related]
[Next] [New Search]
